hydroxyethyl valpromide | 3116-29-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: hydroxyethyl valpromide
• 英文别名: N-(1-hydroxyethyl)-valpromide；N-(2-hydroxyethyl)-2-propylpentanamide；2-Propyl-valeriansaeure-<2-hydroxy-ethylamid>；Valeramide, N-(2-hydroxyethyl)-2-propyl-
• CAS: 3116-29-8
• 化学式: C₁₀H₂₁NO₂
• 分子量: 187.282
• InChiKey: WAJUILWSUFKUQM-UHFFFAOYSA-N

物化性质

• 沸点：
  352.4±25.0 °C(Predicted)
• 密度：
  0.948±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Γ-十八碳三烯酸 、 hydroxyethyl valpromide 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 4-二甲氨基吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以37%的产率得到2-((9Z,12Z,15Z)-octadeca-9,12,15-trienamido)ethyl 2-propylpentanoate
  参考文献：
  名称：

  α-Linolenic Acid–Valproic Acid Conjugates: Toward Single-Molecule Polypharmacology for Multiple Sclerosis

  摘要：

  Multiple sclerosis (MS) is a complex inflammatory, degenerative, and demyelinating disease of the central nervous system. Although treatments exist, MS cannot be cured by available drugs, which primarily target neuroinflammation. Thus, it is feasible that a well concerted polypharmacological approach able to act at multiple points within the intricate network of inflammation, neurodegeneration, and demyelination/remyelination pathways would succeed where other drugs have failed. Starting from reported beneficial effects of α-linolenic acid (ALA) and valproic acid (VPA) in MS, and by applying a rational strategy, we developed a small set of codrugs obtained by conjugating VPA and ALA through proper linkers. A cellular profiling identified 1 as a polypharmacological tool able not only to modulate microglia polarization, but also to counteract neurodegeneration and demyelination and induce oligodendrocyte precursor cell differentiation, by acting on multiple biochemical and epigenetic pathways.

  DOI：

  10.1021/acsmedchemlett.0c00375
• 作为产物：
  描述：

  丙戊酸 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 生成 hydroxyethyl valpromide
  参考文献：
  名称：

  新型AM80衍生物作为抗白血病药物的合成及生物学评价

  摘要：

  合成了一系列新型的AM80衍生物作为抗白血病药物，并通过IR，1 H-NMR和HR-MS光谱证实了其结构。评价所有目标化合物对人白血病HL-60，NB4和K562细胞系的体外抗增殖活性。在这些衍生物中，化合物4g对所有三种人类白血病细胞系的抗增殖活性均强于阳性对照AM80，化合物4b对HL-60和K562细胞的抗增殖活性比AM80高。此外，初步的SAR分析表明AM80与空间位阻小的HDAC抑制剂结合可以产生更有效的抗白血病药物。这些结果将有助于设计更有效的抗白血病药物治疗人类白血病。

  DOI：

  10.1007/s00044-012-0019-9

文献信息

• Benoit-Guyod,J.-L. et al., Bulletin de la Societe Chimique de France, 1965, p. 1660 - 1661
  作者：Benoit-Guyod,J.-L. et al.

  DOI：——

  日期：——
• ——
  作者：Micha Levi、Boris Yagen、Meir Bialer

  DOI：10.1023/a:1012009012850

  日期：——

  Purpose. To explore the utilization of seven novel hydroxamic acid derivatives of valproic acid (VPA) as new antiepileptics.Methods. The study was carried out by investigating the pharmacokinetics of two active compounds in dogs and pharmacodynamics (anticonvulsant activity and neurotoxicity) of valproyl hydroxamic acid and six of its derivatives.Results. Three valproyl hydroxamic acid derivatives: valproyl hydroxamic acid-VPA-HA, N-(1-hydroxyethyl)-valpromide-HEV and N-methoxy valpromide, showed better anticonvulsant activity than VPA at the maximal electroshock (MES) test. The remaining four compounds, O-valproyl-VPA-HA, N-valproyl-O-valproyI-VPA-HA, N-(1-methoxyethyl) valpromide and N-(1,2-dihydroxylpropyl)-valpromide were found to be inactive. Therefore, only the pharmacokinetics of the active compounds VPA-HA and HEV was studied.Conclusions. In contrast to valpromide (VPD) which is biotransformed to VPA, VPA-HA and HEV were found to be stable in vivo to the biotransformation of the amide to its corresponding acid. VPA-HA and HEV showed improved anticonvulsant activity over VPA because of their greater intrinsic activity and not due to better pharmacokinetic characteristics. This paper discusses the structural requirements for active anticonvulsant valproyl hydroxamic acid derivatives.
• Synthesis and biological evaluation of novel AM80 derivatives as antileukemic agents
  作者：Haiyong Bian、Jinhong Feng、Wenfang Xu

  DOI：10.1007/s00044-012-0019-9

  日期：2013.1

  A series of novel AM80 derivatives as antileukemic agents were synthesized and their structures were confirmed by IR, 1H-NMR, and HR-MS spectra. All the target compounds were evaluated for in vitro antiproliferative activities against human leukemic HL-60, NB4, and K562 cell lines. Among these derivatives, compound 4g showed much stronger antiproliferative activities against all the three human leukemic

  合成了一系列新型的AM80衍生物作为抗白血病药物，并通过IR，1 H-NMR和HR-MS光谱证实了其结构。评价所有目标化合物对人白血病HL-60，NB4和K562细胞系的体外抗增殖活性。在这些衍生物中，化合物4g对所有三种人类白血病细胞系的抗增殖活性均强于阳性对照AM80，化合物4b对HL-60和K562细胞的抗增殖活性比AM80高。此外，初步的SAR分析表明AM80与空间位阻小的HDAC抑制剂结合可以产生更有效的抗白血病药物。这些结果将有助于设计更有效的抗白血病药物治疗人类白血病。
• α-Linolenic Acid–Valproic Acid Conjugates: Toward Single-Molecule Polypharmacology for Multiple Sclerosis
  作者：Michele Rossi、Sabrina Petralla、Michele Protti、Monica Baiula、Tereza Kobrlova、Ondrej Soukup、Santi Mario Spampinato、Laura Mercolini、Barbara Monti、Maria Laura Bolognesi

  DOI：10.1021/acsmedchemlett.0c00375

  日期：2020.12.10

  Multiple sclerosis (MS) is a complex inflammatory, degenerative, and demyelinating disease of the central nervous system. Although treatments exist, MS cannot be cured by available drugs, which primarily target neuroinflammation. Thus, it is feasible that a well concerted polypharmacological approach able to act at multiple points within the intricate network of inflammation, neurodegeneration, and demyelination/remyelination pathways would succeed where other drugs have failed. Starting from reported beneficial effects of α-linolenic acid (ALA) and valproic acid (VPA) in MS, and by applying a rational strategy, we developed a small set of codrugs obtained by conjugating VPA and ALA through proper linkers. A cellular profiling identified 1 as a polypharmacological tool able not only to modulate microglia polarization, but also to counteract neurodegeneration and demyelination and induce oligodendrocyte precursor cell differentiation, by acting on multiple biochemical and epigenetic pathways.